Chordia Therapeutics Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Chordia Therapeutics's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Next Earnings Update | 11 Oct 2024 |
Recent past performance updates
Recent updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Chordia Therapeutics has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses Breakdown
How Chordia Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|
Quality Earnings: Insufficient data to determine if 190A has high quality earnings.
Growing Profit Margin: Insufficient data to determine if 190A's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 190A's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 190A's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: Insufficient data to determine if 190A's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: 190A has a negative Return on Equity (0%), as it is currently unprofitable.